**Title:- The Review Article On Diabetes**

**Name :- 1} Sheetal Hanuman Sangle**

 **2} Neha Jayram Patil**

 **3} Bhagyashree Bapu Pawar**

 **4} Purvesh Subhash Chavhan**

 **5} Chetan Vasant Rathod**

**Guidance By:- 1} Mr. Awais Mohmmad**

 **2} Mr. Nazeer Ahmed**

**Abstract**

 Abbreviations: DM, diabetes; T1D, type-1-disaccharide; T2D, type-2-disaccharide; LADA, potential autoimmune-disaccharide in adults. Diabetes in women, potential autoimmune adolescents. GAD, glutamate decarboxylase; Mody, Ripe Harting Diabetes in Boys. HNF-1, liver transcription factor 1; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test. HBA1C, hemoglobin A1c; TNF-î±, tumor necrosis factor alpha; nf-îºb, core factor kappa B; jnks, janus kinase way; IRS-1, insulin receptor substrate 1; C-RP, C-reactive protein; MCP-1, monocyte chemical inducible protein; IL-6, Interukin-6; ifn-î³, interferonî³; PAI-1, Plasminogen activator inhibitor 1; Age, advanced glycation products; ROS, reactive oxygen species; Anger, receptor advanced glycation final products. nk, natural killer; INOS, inducible nitrogen oxide synthase.

 CVD, cardiovascular disease; AT, adipose tissue; MCP-1, monocyte chemoattractant protein-1; LDL, low-dense lipoprotein; PPAR-é£, peroxisomaprofiler factor-activated receptor gamma. NSAIDS, non-steroidal anti-inflammatory drugs; bats, brown adipose tissue; wat, white adipose tissue; GSIS, glucose stimulated insulin secretion. FFA, free fatty acids; catalase; GLT, glutathione; SOD, Superoxid Dismmutase; Rooh, Reactive Hydroperoxide; MDA, Marondiahide; etc. Electronic transport chain. MAM, mitochondria-associated ER membrane; TLRS, fee-like receptors. CEB/PS, CCAAT enhancer binding protein. MEF2, myocyte-Enhancer-Factor 2; HIF-1, hypoxia-inducing factor alpha. IS, insulin signaling.

 IRS-1, insulin receptor Substrate 1; IKK-B, an inhibitor of core factor Kappa B. GSK-3, glycogenic incineration kinase 3; AMPK, AMP-activated protein kinase. Mtor, Mammalian destinations by rapamycin. p38 MAPK, p38 mitogen-activated protein kinase. MRC, mitochondrial airways; Doug, diacylglycerin; IS. , insulin signaling. LPS, lipopolysaccharide; SCFA, short-chain fatty acids; IP-10, IFN-inducible protein 10; IMP, imidazole propion; BCAA, branched amino acids; TMAO, TRI Methylamine N-oxide. NAFLD, non-alcoholic fatty liver disease; HCV, hepatitis-C virus; Nash, non-alcoholic fatty hepatitis; CIN, contrasting nephropathy; GFR, glomerular filtration rate. TGF-²1, conversion growth factor beta 1; Jak-Stat, Janus Kinase signal converter and transcriptional activator. SMPDL3B, Sphingomyelin phosphodiesterasenas acid-like 3b; Jam, molecular proteins due to junction adhesion.

 Camkii, Nitric Oxide (NO) Ca2+/Calmodulin-dependent Protein Kinase II; SERCA2A, Myocytoplasmic/Elastic Endoplasmic Reticulum Ca2+ ATPase 2a; HDACS, Histone-Deacetylase; PBMC, Mononuclear Cells in Peripheral Blood. Tirap, maut/IL-1R Domaina-containing adapter protein. Hif1î±, hypoxia-inducible factor 1 alpha; VEGF-1, vascular endothelial growth factor.

**Introduction**

Diabetes is a chronic disorder of carbohydrates, fats and protein metabolism. The defect or defect response of the insulin Secretary, used to impair carbohydrates (glucose), is a characteristic of diabetes, and similar to the resulting hyperglycemia [1] diabetes (DM). Insulin or rarely missing Insulin activity (insulin resistance) [2] International Diabetes Federation (IDF) estimates the total number of diabetics to 40 million in India, which will continue to increase in 2025. The hormones of insulin and glucagon are both secreted by the pancreas.

 Insulin is secreted by beta (ã) cells and glucagon, and both alpha (±) cells are located on the island of Langehan. Insulin lowers blood glucose levels through glycogesis and transport transporting to muscles, liver, and adipose tissue. Although neural tissue and red blood cells are not required for glucose exploitation, alpha cells (±) play an important role in the regulation of blood glucose by producing glucagon, and increase blood glucose levels by increasing blood glucose levels [4, 5]. Malignant tumors in the future lifespan of the fetus after birth, in addition to increased risk of obesity, metabolism and cardiovascular disorders [6].

Type-II diabetes accounts for 80% to 90% of all cases of diabetes. Geographical variation can contribute to the size of problems and general morbidity and mortality [7, 8]. Furthermore, people with diabetes who perform moderate physical activity have an invisible risk of death [10]. See figures (1 and 2). In diabetes, there is an abnormality in either synthesis or insulin secretion. For example, type 1 diabetes mellitus (T1DM) and stenosis in pancreatic passage, or development of resistance to insulin, or production of production standardized (T2DM) and standard production volume (T2DM**)**

**Classification Of Diabetes Mellitus**

****

**Risk Factor of Diabetes:**

 Diabetic patients can have many related comorbidities and risk factors to consider when classifying subtypes.

1] These comorbidities include cardiovascular disease (CVD)

2] Genetic factors

3] GI symptoms

4] Increased fasting

5]Tragecorge of HBA1C mirror.

**Sign And Symptoms of Diabetes:**

1] Frequent Urination

2] Excessive Thirst

3] Increased Hunger

4] Unexplained Weight Loss

5] Fatigue and Weakness

6] Blurred Vision

7] Slow-healing Wounds

8] Frequent Infections

9] Bedwetting in Children

10] Itchy Skin

**Causes of Diabetes:**

Cellular glucoreceptor destruction or abnormality responds to higher glucose concentrations or relative lack of cells. In both cases, insulin secretion is affected. MayProgression to cell damage [12]. The main theory of microbial diseases leads to the direct effects of neurohypoxia and hyperglycemia [13].

1. Reduced sensitivity of peripheral tissues compared to insulin:Reduced number of insulin receptors, regulation of insulin receptors. Many hypersensitivity and hyperinsulinism are normal blood glucose. And I have Related delipidemia, hyperuria, abdominal obesity. Therefore, there is a relative insulin resistance, especially in the liver, muscle and fat.Hyperinsulinaemie was associated with vascular disorders [11].

2. Excess of hyperglycemic hormone (glucagon) etc./Obesity; Causes relative insulin deficiency - â cells remain. Two theories demonstrate abnormalities in nitrogen metabolism and nitrogen oxides, which resulted in altered pericytic perimatous perimatous flow and altered nerve damage [12].

3. Other rare forms of diabetes are due to certain genetic defects (type 3), such as onset of maturation, such as diabetes, which is a modi (mody) other endocrine disorder.[11].

4. Imbalance in certain receptors can cause diabetes mellitus. Some specific receptors include glucagon-like peptide-1 (GLP-1) receptor, peroxysomen growth factor-activated (ppppparî³), beta3 (ã3) glowing rock receptor $± glycosidase, dipeptidylpeptidylepeptidyevebrigs °C.

5. Current investigations of diabetic neuropathy focus on oxidative stress, advanced glycated terminal products, protein kinase C and polyol pathways [13].

**Therapy Of Diabetes:**

1. Stem Cell Therapy:

 Researchers have shown that monoza/macrophages are the main actors contributing to these chronic inflammation and insulin resistance in T2DM patients [14]. Stem Cell Teacher Therapy is a new technology designed to be controlled or vice versa. The procedure includes blood collection via a closed system Washing of lymphocytes from thoroughbred co-culture Adhering blood multi-electrified cells ([15].

1. Antioxidant Therapy:

 A variety of antioxidants, including vitamins, dietary supplements, and active substances and drugs with antioxidant effects derived from plant-based sources, have been used to treat oxidative stress in T2DM patients. Vitamin C, vitamin E, and î² carotene are ideal dietary supplements for oxidative stress and its complications. [16]Antioxidants play an important role in reducing the risk of diabetes development and its complications.

3. Anti-inflammatory therapy:

Changes indicate that inflammation plays a critical role in the pathogenesis of T2DM and its complications[17, 18].T2dm, especially in adipose tissue, pancreatic islets, liver, vasculature and circulating leukocytes,[19], altered specific cytokines and chemokines, alter specific cytokines and chemokines, with attractive aphotes activated states. Different leukzytes.[19, 20] Immunomodulatory drilling is provided**.**

**Treament of Diabetes:**

Diabetes Diagnosis of diabetes in asymptomatic subjects should be based on a single abnormal blood glucose level. If a diabetes diagnosis is made, the outcome is quite a lifetime [21], so the clinician must be sure that the diagnosis will be fully determined. Diagnosis of diabetes includes urine glucose, blood glucose, glucose tolerance tests, renal thresholds for glucose, decreased glucose tolerance, increased glucose tolerance, renal diabetes, renal glycose, dilated glucose tolerance, and colt glucose tolerance tests. This treatment is intended to overcome the intentional cause and provide a high dose of normal insulin. Insulin requests will return to normal as soon as the condition is checked.

1. To bring the disturbed metabolism of diabetes to almost normalize, this responds to comfort and safety.

2. Prevent or delay the progression of short- and long-term risks of disease.

3. Perform this illuminated care to communicate knowledge, motivation, and.

**Etiology Of Diabetes:**

The term etiology comes from the Greek word aetiologia. Aetiology is therefore defined as the science of discovery of the causes and causes of diseases to occur.

1.Viruses may also play a role in the pathogenesis of diabeteslike coxsackieb.

2. Mumps and rubella viruses have been shown to produce all morphological changes in islet cell structure.

3. The genetic role in the pathogenesis of diabetes is controversial. Genetic features may make one of the above viruses more susceptible to greater influence [22].

**Conclusion:**

 Diabetes is a serious complication of life today. Lifestyle and the current environment of today's environment play an important role in This review gives you the idea of ​​diabetes. This study was supported by the Korean Government (MSIT) (No. CAP23011), the Kist Institutional Program (2E32333), and the National Research Council of Science and Technology (NST) (NST) by KDDF's 2ME1650. Ahmed Elkamhawi has expanded his gratitude to support this work in the Kist School Partnership project and would like to thank Mana University's Technology Innovation (TIO) for the highly effective contributions in implementing this project

**Reference:-**

1. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.

2. Ross and Wilson. Anatomy and Pathophysiology in Health and Illness, Churchill Livingstone Elsevier, 11the edition, 2010, 227-229.

3. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE. Defective regulatory and effector T cell functions in patients with FOXP3 mutations, J Clin Invest. 2006; 116:1713-1722,

4. Wassmuth R, Lernmark A. The genetics of susceptibility to diabetes, ClinImmunol, Immunopathol. 1989; 53:358-399,

5. Atkinson MA, Eisenbarth GS. Type 1 diabetes new perspectives on disease pathogenesis and treatment, Lancet. 2001; 358:221-229.

6. Hoet JJ, Tripathy BB, Rao RH, Yajnik CS. Malnutrition and diabetes in the tropics, Diabetes Care. 1996; 19:1014-17,

7. Tripathy BB, Samal KC. Overview and consensus statement on diabetes in tropical areas, Diabetes Metab Rev. 1997; 13:63-76.

8. Betterle C, Zanette F, Pedini B, Presotto F, Rapp LB, Monsciotti CM et al., Clinical and subclinical organ–specific autoimmune manifestations in type 1 (insulin–dependent) diabetic patients and their first**-**degreerelatives, Diabetologia. 1983; 26:431-36.

9. Bearse MA Jr, Han Y, Schneck ME, Barez S, Jacobsen C. Localmultifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy, Invest Ophthalmol Vis Sci. 2004; 45:3259-3265.

10. Zimmet PZ, Tuomi T, Mackay R, Rowley MJ, Knowles W, Cohen M et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency, Diabetic Med. 1994; 11:299-303.

11. Gupta OP, Joshi MH, Daves SK. Prevalence of Diabetes in India, Adv Metab Disord. 1978; 9:147-65.

12. Alemu S, Dessie A, Seid E. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutrition-related diabetes, Diabetologia. 2009; 52:1842-1845.

13. Wild S, Roglic G, Green A, Sicree R, King. Global prevalence of diabetes: Estimates for the year 2000and projections for 2030, Diabetes Care. 2004; 27:1047-53.

14. Kadiki OA, Reddy MR, Marzouk AA. Incidence of insulin-dependent diabetes(IDDM) and non-insulin-dependent diabetes (NIDDM) (0-34 years at onset) in Benghazi, Libya, Diabetes Res Clin Pract. 1996; 32:165-173.

15. The World Health Report. Shaping the future, 2003.

16. Shaw J, Zimmet P, de Courten M, Dowse G, Chitson P, Gareeboo Het al., Impaired fasting glucose or impaired glucose tolerance, Diabetes Care. 1999; 22:399-402

17. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M. Rising prevalence of NIDDM in an urban population in India Diabetologia1997; 40:232-237.

18. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance, Diabetes Atlas International Diabetes Federation, 2006, 15-103.

19. Sridhar GR, Rao PV, Ahuja MMS. Epidemiology of diabetes and its complications In: RSSDI textbook of diabetesmellitus, 2002, 95-112.

20. WHO. Study Group Diabetes Mellitus, Technical report series no.727, World Health Organisation, Geneva, 1985.

21.Mohan V, Pradeepa R. Epidemiology of diabetes in different regions of India. 2009; 22:1-18.

22. Alemu S, Dessie A, Seid E. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutrition-related diabetes, Diabetologia. 2009; 52:1842-1845.